Table 1 Baseline characteristics of patients
Characteristics | All patients (N = 147) | Patients who were evaluated for SVR (N = 132) | Patients with treatment discontinuation or loss to follow-up (N = 15) |
|---|---|---|---|
Age*, mean ± SD (years) | 41.1 ± 11.6 | 41.2 ± 11.9 | 40.1 ± 8.7 |
Gender, n (%) | |||
Male | 139 (94.6%) | 126 (95.5%) | 13 (86.7%) |
Female | 8 (5.4%) | 6 (4.5%) | 2 (13.3%) |
Hereditary bleeding disorder types, n (%) | |||
Hemophilia A | 113 (76.9%) | 106 (80.3%) | 7 (46.7%) |
Hemophilia B | 19 (12.9%) | 14 (10.6%) | 5 (33.3%) |
VWD | 8 (5.4%) | 6 (4.5%) | 2 (13.3%) |
Glanzmann | 1 (0.7%) | 1 (0.8%) | 0 (0%) |
Other disorders | 6 (4.1%) | 5 (3.8%) | 1 (6.7%) |
HIV co-infection, n (%) | 6 (4.1%) | 5 (3.8%) | 1 (6.7%) |
HBV co-infection, n (%) | 0 (0%) | 0 (0%) | 0 (0%) |
Platelet count**, mean ± SD (109/L) | 200.0 ± 59.3 | 197.8 ± 59.4 | 219.8 ± 56.6 |
Hemoglobin**, Median (IQR) (g/dL) | 15.7 (14.3–16.9) | 15.7 (14.4–16.9) | 15.3 (11.1–17.3) |
AST**, Median (IQR) (IU/L) | 38 (27–55) | 38 (27–55) | 38 (32–76) |
ALT**, Median (IQR) (IU/L) | 42 (27–70) | 42 (30–70) | 46 (19–72.5) |
HCV RNA*, mean ± SD (log10 IU/mL) | 6.0 ± 0.8 | 5.9 ± 0.8 | 6.2 ± 0.5 |
Liver stiffness measurement (Metavir score)*, n (%) | |||
F0–F2 | 75 (54%) | 66 (52.8%) | 9 (64.3%) |
F2–F4 | 33 (23.7%) | 31 (24.8%) | 2 (14.3%) |
F4 | 31 (22.3%) | 28 (22.4%) | 3 (21.4%) |
Cirrhosis, n (%) | |||
Non-cirrhotic | 110 (74.8%) | 99 (75%) | 11 (73.3%) |
Compensated cirrhosis | 32 (21.8%) | 29 (22.0%) | 3 (20%) |
Decompensated cirrhosis | 5 (3.4%) | 4 (3.0%) | 1 (6.7%) |
HCV genotype*, n (%) | |||
1 | 98 (68.1%) | 89 (68.5%) | 9 (64.3%) |
2 | 2 (1.4%) | 2 (1.5%) | 0 (0%) |
3 | 30 (20.8%) | 27 (20.8%) | 3 (21.4%) |
4 | 4 (2.8%) | 4 (3.1%) | 0 (0%) |
Mix | 10 (6.9%) | 8 (6.1%) | 2 (14.3%) |
Previous treatment experience, n (%) | |||
Treatment naïve | 68 (46.3%) | 61 (46.2%) | 7 (46.7%) |
Interferon-experienced | 79 (53.7%) | 71 (53.8%) | 8 (53.3%) |
DAA-experienced | 0 (0%) | 0 (0%) | 0 (0%) |